Advanced pancreatic ductal adenocarcinoma - Complexities of treatment and emerging therapeutic options.
AuthorDiwakarla, C; Hannan, K; Hein, N; Yip, D
Source TitleWorld Journal of Gastroenterology
PublisherBaishideng Publishing Group Inc.
University of Melbourne Author/sHannan, Katherine
AffiliationBiochemistry and Molecular Biology
Document TypeJournal Article
CitationsDiwakarla, C., Hannan, K., Hein, N. & Yip, D. (2017). Advanced pancreatic ductal adenocarcinoma - Complexities of treatment and emerging therapeutic options.. World J Gastroenterol, 23 (13), pp.2276-2285. https://doi.org/10.3748/wjg.v23.i13.2276.
Access StatusOpen Access
Open Access at PMChttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC5385394
Pancreatic ductal adenocarcinoma is a devastating disease with a poor prognosis regardless of stage. To date the mainstay of therapy for advanced disease has been chemotherapy with little incremental improvements in outcome. Despite extensive research investigating new treatment options the current practices continue to utilise fluorouracil or gemcitabine containing combinations. The need for novel therapeutic approaches is mandated by the ongoing poor survival rates associated with this disease. One such approach may include manipulation of ribosome biogenesis and the nucleolar stress response, which has recently been applied to haematological malignancies such as lymphoma and prostate cancer with promising results. This review will focus on the current therapeutic options for pancreatic ductal adenocarcinoma and the complexities associated with developing novel treatments, with a particular emphasis on the role of the nucleolus as a treatment strategy.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References